Which pricing strategy is specifically protected by the Orphan Drug Act to encourage pharmaceutical companies to develop treatments for rare diseases?

Orphan drugs are medications developed specifically for rare diseases affecting small patient populations. Due to the limited market size, these drugs often have unique pricing considerations compared to mainstream medications. This poll tests your knowledge about the pricing strategies employed in the orphan drug market, which has become a significant segment of the pharmaceutical industry in recent years. Understanding these strategies provides insight into the complex economics of developing treatments for rare conditions.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Premium pricing with market exclusivity for 7 years
Cost-plus pricing with 50% markup guarantees
Reference pricing based on similar therapies regardless of development costs
Value-based pricing with mandatory insurance coverage